Clinical Trial Update: Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for MG-K10, a humanized monoclonal antibody, investigated in patients with atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• MG-K10

Snippet

Sponsor: Shanghai Mabgeek Biotech.Co.Ltd | Conditions: Atopic Dermatitis | Phase 3 | Status: UNKNOWN